Tobias Tritschler

Tobias Tritschler

Auto-generated profile, based on publicly available information

Tobias Tritschler

Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Chest
Verified
Journal Article
Closed access
LMLisa K. Moores
Lisa K. Moores
TTTobias Tritschler
Tobias Tritschler
SBShari Brosnahan
Shari Brosnahan
MCMarc Carrier
Marc Carrier
JCJacob F. Collen
Jacob F. Collen
PWPhilip Wells
Philip Wells

16 October 2018 in JAMA
Verified
Journal Article
Closed access
PDF file
TTTobias Tritschler
Tobias Tritschler
NKNoémie Kraaijpoel
Noémie Kraaijpoel
GGGrégoire Le Gal
Grégoire Le Gal
PWPhilip S. Wells
Philip S. Wells
Importance Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common and potentially fatal disease. Objective To summarize the advances in diagnosis and treatment of VTE of the past 5 years. Evidence Review A systematic search was conducted in EMBASE Classic, EMBASE, Ovid MEDLINE, and other nonindexed citations using broad terms for diagnosis and treatment of VTE to find systematic reviews and meta-analyses, randomized trials, and prospective cohort studies published between January 1, 2013, and July 31, 2018. The 10th edition of the American College of Chest Physicians Antithrombotic Therapy Guidelines was screened to identify additional studies. Screening of titles, abstracts, and, subsequently, full-text articles was performed in duplicate, as well as data extraction and risk-of-bias assessment of the included articles. Findings Thirty-two articles were included in this review. The application of an age-adjusted D-dimer threshold in patients with suspected PE has increased the number of patients in whom imaging can be withheld. The Pulmonary Embolism Rule-Out Criteria safely exclude PE when the pretest probability is low. The introduction of direct oral anticoagulants has allowed for a simplified treatment of VTE with a lower risk of bleeding regardless of etiology or extent of the VTE (except for massive PE) and has made extended secondary prevention more acceptable. Thrombolysis is best reserved for patients with massive PE or those with DVT and threatened limb loss. Insertion of inferior vena cava filters should be avoided unless anticoagulation is absolutely contraindicated in patients with recent acute VTE. Graduated compression stockings are no longer recommended to treat DVT but may be used when acute or chronic symptoms are present. Anticoagulation may no longer be indicated for patients with isolated distal DVT at low risk of recurrence. Conclusions and Relevance Over the past 5 years, substantial progress has been made in VTE management, allowing for diagnostic and therapeutic strategies tailored to individual patient characteristics, preferences, and values.

1 November 2020 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
TTTobias Tritschler
Tobias Tritschler
MMMarie‐Eve Mathieu
Marie‐Eve Mathieu
LSLeslie Skeith
Leslie Skeith
MRMarc Rodger
Marc Rodger
SMSaskia Middeldorp
Saskia Middeldorp
GGGrégoire Le Gal
Grégoire Le Gal

12 March 2026 in New England Journal of Medicine
Verified
Journal Article
Closed access
LCLana A. Castellucci
Lana A. Castellucci
VCVivien M. Chen
Vivien M. Chen
MKMichael J. Kovacs
Michael J. Kovacs
ALAlejandro Lazo-Langner
Alejandro Lazo-Langner
PGPeter Greenstreet
Peter Greenstreet
MRMarc Rodger
Marc Rodger
Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk between the two medications. In an international trial with a prospective, randomized, open-label, blinded end-point design, we assigned, in a 1:1 ratio, eligible patients with acute symptomatic pulmonary embolism or proximal deep-vein thrombosis to receive apixaban or rivaroxaban for 3 months. Apixaban was given at a dose of 10 mg twice daily for 7 days followed by 5 mg twice daily, and rivaroxaban was given at a dose of 15 mg twice daily for 21 days followed by 20 mg daily. The primary outcome was clinically relevant bleeding, a composite of major bleeding or clinically relevant nonmajor bleeding, as defined according to the International Society on Thrombosis and Haemostasis, during the 3-month trial period. Secondary outcomes included death from any cause. A total of 2760 patients underwent randomization: 1370 to the apixaban group and 1390 to the rivaroxaban group. A primary-outcome event occurred in 44 of 1345 patients (3.3%) in the apixaban group and 96 of 1355 patients (7.1%) in the rivaroxaban group (relative risk, 0.46; 95% confidence interval [CI], 0.33 to 0.65; P<0.001). Death from any cause occurred in 1 patient (0.1%) in the apixaban group and in 4 patients (0.3%) in the rivaroxaban group (relative risk, 0.25; 95% CI, 0.03 to 2.26). Serious adverse events unrelated to bleeding or venous thrombosis occurred in 36 patients (2.7%) in the apixaban group and in 30 patients (2.2%) in the rivaroxaban group. Among patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. (Funded by the Canadian Institutes of Health Research and others; COBRRA ClinicalTrials.gov number, NCT03266783.).

4 June 2020 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
TTTobias Tritschler
Tobias Tritschler
NKNoémie Kraaijpoel
Noémie Kraaijpoel
PGPhilippe Girard
Philippe Girard
HBHarry R. Büller
Harry R. Büller
NLNicole Langlois
Nicole Langlois
FDFor The Subcommittee On Predictive And Diagnostic Variables In Thrombotic Disease
For The Subcommittee On Predictive And Diagnostic Variables In Thrombotic Disease

1 July 2017 in Thrombosis Research
Verified
Journal Article
Closed access
TTT. Tritschler
T. Tritschler
DAD. Aujesky
D. Aujesky